Kavita Y Sarin, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sarin’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A109187 · Current
Licensed to practise in California · since 2009 · expires 2026-11-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$54,856
Medicare paid this office $54,856 for 210 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 98 | $15,316 | $112 |
| Short return visit (20+ min) | 92 | $8,995 | $78 |
| Destruction of precancer skin growth, 1 growth | 99 | $7,862 | $53 |
| Destruction of skin growth, 1-14 growths | 40 | $4,914 | $105 |
| Biopsy of related skin growth, first growth | 44 | $4,232 | $90 |
See all 9 services
| Return visit (30+ min) | 98 | $15,316 | $112 |
| Short return visit (20+ min) | 92 | $8,995 | $78 |
| Destruction of precancer skin growth, 1 growth | 99 | $7,862 | $53 |
| Destruction of skin growth, 1-14 growths | 40 | $4,914 | $105 |
| Biopsy of related skin growth, first growth | 44 | $4,232 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 69 | $2,687 | $7 |
| New patient visit (30+ min) | 19 | $1,556 | $82 |
| Short return visit | 21 | $1,277 | $56 |
| Biopsy of related skin growth, each additional growth | 12 | $829 | $52 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 309 | More than 82% of doctors who do this |
| Skin biopsy | 78 | More than 73% of doctors who do this |
Who their Medicare patients are
210 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 16% · Women 61% · Also on Medicaid 8% · Health risk score 1.07. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 58% · Cancer 21% · Coronary heart disease 19% · Diabetes 16% · Chronic kidney disease 16% · Atrial fibrillation 12% · Depression 12% · Heart failure 9% · Stroke 8%.
The office billed $250,860, Medicare allowed $76,367 and paid $54,856; for 1,041 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 210 | 1,041 | 75 | 1.07 | $250,860 | $54,856 |
| 2023 | 190 | 1,035 | 76 | 1.06 | $558,750 | $51,918 |
| 2022 | 171 | 964 | 75 | 1.01 | $645,922 | $48,071 |
| 2021 | 203 | 1,186 | 75 | 1.00 | $640,197 | $57,468 |
| 2020 | 175 | 846 | 75 | 1.00 | $393,354 | $30,922 |
| 2019 | 195 | 1,151 | 76 | 1.04 | $197,008 | $33,832 |
| 2018 | 218 | 1,290 | 76 | 1.08 | $132,912 | $35,837 |
| 2017 | 216 | 1,329 | 75 | 1.01 | $141,849 | $36,170 |
| 2016 | 256 | 1,423 | 76 | 1.01 | $172,840 | $44,850 |
| 2015 | 234 | 1,280 | 76 | 0.98 | $169,039 | $43,705 |
| 2014 | 312 | 1,128 | 74 | 1.04 | $159,923 | $41,110 |
| 2013 | 227 | 645 | 73 | 1.14 | $112,915 | $32,353 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 80 | $13,441 | $114 |
| Short return visit (20+ min) | 108 | $11,290 | $78 |
| Destruction of precancer skin growth, 1 growth | 81 | $6,231 | $47 |
| Destruction of skin growth, 1-14 growths | 41 | $5,510 | $102 |
| Biopsy of related skin growth, first growth | 31 | $3,328 | $95 |
| Destruction of precancer skin growth, 2-14 growths | 61 | $2,834 | $7 |
| New patient visit (45+ min) | 15 | $2,101 | $140 |
| Short return visit | 12 | $595 | $50 |
| Telehealth originating site facility fee | 11 | $247 | $21 |
2022: 8 services
| Return visit (30+ min) | 84 | $12,912 | $113 |
| Short return visit (20+ min) | 85 | $9,039 | $75 |
| Destruction of skin growth, 1-14 growths | 50 | $7,033 | $103 |
| Destruction of precancer skin growth, 1 growth | 75 | $4,891 | $43 |
| Biopsy of related skin growth, first growth | 28 | $2,918 | $88 |
| Destruction of precancer skin growth, 2-14 growths | 57 | $2,395 | $6 |
| Biopsy of related skin growth, each additional growth | 11 | $728 | $52 |
| Short return visit | 11 | $689 | $53 |
2021: 9 services
| Return visit (30+ min) | 98 | $16,672 | $115 |
| Short return visit (20+ min) | 111 | $12,059 | $76 |
| Destruction of precancer skin growth, 1 growth | 91 | $6,333 | $46 |
| Destruction of skin growth, 1-14 growths | 46 | $5,621 | $104 |
| Biopsy of related skin growth, first growth | 49 | $4,622 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 69 | $2,493 | $6 |
| New patient visit (30+ min) | 14 | $1,328 | $95 |
| Biopsy of related skin growth, each additional growth | 16 | $1,003 | $48 |
| Telehealth originating site facility fee | 44 | $1,000 | $19 |
2020: 9 services
| Short return visit (20+ min) | 111 | $10,260 | $60 |
| Return visit (30+ min) | 41 | $4,445 | $87 |
| Destruction of precancer skin growth, 1 growth | 64 | $3,680 | $42 |
| Destruction of skin growth, 1-14 growths | 28 | $3,206 | $84 |
| Biopsy of related skin growth, first growth | 19 | $1,833 | $83 |
| Destruction of precancer skin growth, 2-14 growths | 52 | $1,777 | $5 |
| New patient visit (30+ min) | 22 | $1,718 | $78 |
| Telehealth originating site facility fee | 37 | $853 | $21 |
| Short return visit | 11 | $391 | $30 |
2019: 8 services
| Short return visit (20+ min) | 120 | $7,612 | $45 |
| Destruction of precancer skin growth, 1 growth | 92 | $5,414 | $42 |
| Return visit (30+ min) | 35 | $4,162 | $68 |
| Destruction of skin growth, 1-14 growths | 39 | $3,128 | $65 |
| New patient visit (30+ min) | 24 | $1,732 | $72 |
| Destruction of precancer skin growth, 2-14 growths | 75 | $1,335 | $3 |
| Biopsy of related skin growth, first growth | 38 | $1,100 | $24 |
| Short return visit | 23 | $653 | $25 |
2018: 9 services
| Short return visit (20+ min) | 123 | $7,658 | $40 |
| Destruction of precancer skin growth, 1 growth | 102 | $6,012 | $38 |
| Return visit (30+ min) | 70 | $5,974 | $60 |
| Destruction of skin growth, 1-14 growths | 51 | $3,967 | $59 |
| New patient visit (30+ min) | 31 | $1,852 | $60 |
| Biopsy of single growth of skin and/or tissue | 55 | $1,746 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $948 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 12 | $585 | $18 |
| Short return visit | 17 | $349 | $18 |
2017: 9 services
| Return visit (30+ min) | 87 | $7,874 | $62 |
| Short return visit (20+ min) | 124 | $7,794 | $40 |
| Destruction of precancer skin growth, 1 growth | 107 | $6,511 | $39 |
| Destruction of skin growth, 1-14 growths | 64 | $4,514 | $57 |
| Biopsy of single growth of skin and/or tissue | 49 | $1,556 | $26 |
| New patient visit (30+ min) | 20 | $1,188 | $59 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $1,045 | $2 |
| Short return visit | 20 | $475 | $20 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $226 | $14 |
2016: 9 services
| Return visit (30+ min) | 111 | $10,061 | $66 |
| Destruction of precancer skin growth, 1 growth | 127 | $7,845 | $41 |
| Short return visit (20+ min) | 100 | $6,458 | $43 |
| Destruction of skin growth, 1-14 growths | 74 | $5,248 | $60 |
| New patient visit (30+ min) | 54 | $3,228 | $60 |
| New patient visit (45+ min) | 26 | $2,886 | $111 |
| Biopsy of single growth of skin and/or tissue | 61 | $2,062 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 96 | $1,189 | $2 |
| Short return visit | 29 | $709 | $22 |
2015: 10 services
| Return visit (30+ min) | 87 | $8,693 | $68 |
| Destruction of precancer skin growth, 1 growth | 112 | $7,990 | $45 |
| Short return visit (20+ min) | 91 | $5,583 | $43 |
| New patient visit (30+ min) | 72 | $4,446 | $62 |
| Destruction of skin growth, 1-14 growths | 57 | $4,261 | $66 |
| New patient visit (45+ min) | 37 | $3,629 | $98 |
| Biopsy of single growth of skin and/or tissue | 55 | $2,065 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 86 | $1,040 | $2 |
| Short return visit | 26 | $706 | $23 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $340 | $23 |
2014: 10 services
| Return visit (30+ min) | 83 | $7,582 | $65 |
| New patient visit (45+ min) | 70 | $7,406 | $106 |
| New patient visit (30+ min) | 109 | $5,842 | $54 |
| Destruction of precancer skin growth, 1 growth | 97 | $5,356 | $43 |
| Short return visit (20+ min) | 98 | $5,111 | $40 |
| Destruction of skin growth, 1-14 growths | 52 | $3,414 | $59 |
| Biopsy of single growth of skin and/or tissue | 72 | $2,672 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $788 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $489 | $22 |
| Short return visit | 16 | $268 | $17 |
2013: 8 services
| New patient visit (45+ min) | 100 | $10,654 | $107 |
| Return visit (30+ min) | 54 | $4,325 | $68 |
| Short return visit (20+ min) | 59 | $3,252 | $43 |
| New patient visit (30+ min) | 47 | $2,898 | $62 |
| Destruction of skin growth, 1-14 growths | 46 | $2,784 | $61 |
| Destruction of precancer skin growth, 1 growth | 53 | $2,723 | $45 |
| Biopsy of single growth of skin and/or tissue | 47 | $1,914 | $36 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $550 | $4 |
Drugs they prescribed that Part D paid
$217,686
Pharmacies billed $217,686 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 322) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
290 generic and 32 brand-name prescriptions · $217,686 in drug cost · 23 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Doxepin | 12 | $864 | $72 |
| Fluorouracil | 15 | $837 | $56 |
| Clindamycin Phosphate | 16 | $475 | $30 |
| Ketoconazole | 26 | $401 | $15 |
| Clobetasol Propionate | 15 | $349 | $23 |
See all 10 drugs
| Doxepin | 12 | $864 | $72 |
| Fluorouracil | 15 | $837 | $56 |
| Clindamycin Phosphate | 16 | $475 | $30 |
| Ketoconazole | 26 | $401 | $15 |
| Clobetasol Propionate | 15 | $349 | $23 |
| Triamcinolone Acetonide | 20 | $200 | $10 |
| Methotrexate | 20 | $160 | $8 |
| Hydrocortisone | 17 | $101 | $6 |
| Mupirocin | 12 | $88 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $20 | $2 |
Year by year
| 2024 | 322 | 90 | 0% (0) | 10% | $217,686 |
| 2023 | 236 | 74 | 0% (0) | 12% | $203,422 |
| 2022 | 161 | 53 | 0% (0) | None | $35,900 |
| 2021 | 172 | 66 | 0% (0) | 7% | $80,291 |
| 2020 | 183 | 65 | 0% (0) | 20% | $326,751 |
| 2019 | 279 | 85 | 0% (0) | 15% | $329,484 |
| 2018 | 326 | 98 | 0% (0) | 21% | $439,524 |
| 2017 | 320 | 93 | 0% (0) | 19% | $329,339 |
| 2016 | 300 | 106 | None | 23% | $96,654 |
| 2015 | 331 | 111 | None | None | $112,418 |
| 2014 | 420 | 135 | 0% (0) | None | $57,203 |
| 2013 | 251 | 112 | 0% (0) | None | $31,302 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Dupixent | 18 | $72,165 | $4,009 |
| Ketoconazole | 26 | $1,145 | $44 |
| Fluorouracil | 16 | $1,049 | $66 |
| Clobetasol Propionate | 12 | $636 | $53 |
| Clindamycin Phosphate | 11 | $380 | $35 |
| Triamcinolone Acetonide | 14 | $221 | $16 |
2022: 2 drugs
| Ketoconazole | 37 | $1,398 | $38 |
| Triamcinolone Acetonide | 20 | $171 | $9 |
2021: 3 drugs
| Clobetasol Propionate | 15 | $2,816 | $188 |
| Ketoconazole | 16 | $408 | $25 |
| Triamcinolone Acetonide | 12 | $114 | $10 |
2020: 4 drugs
| Humira(Cf) Pen Crohn'S-UC-Hs | 14 | $219,157 | $15,654 |
| Fluorouracil | 14 | $1,604 | $115 |
| Fluocinonide | 13 | $879 | $68 |
| Triamcinolone Acetonide | 11 | $122 | $11 |
2019: 8 drugs
| Acitretin | 16 | $2,851 | $178 |
| Fluorouracil | 15 | $1,852 | $123 |
| Doxycycline Hyclate | 18 | $888 | $49 |
| Fluocinonide | 11 | $674 | $61 |
| Methotrexate | 13 | $658 | $51 |
| Triamcinolone Acetonide | 27 | $358 | $13 |
| Ketoconazole | 17 | $324 | $19 |
| Mupirocin | 13 | $87 | $7 |
2018: 11 drugs
| Humira | 16 | $212,287 | $13,268 |
| Fluorouracil | 18 | $3,041 | $169 |
| Metronidazole | 22 | $1,582 | $72 |
| Clindamycin Phosphate | 15 | $1,517 | $101 |
| Betamethasone Dipropionate | 18 | $1,443 | $80 |
| Clobetasol Propionate | 12 | $1,052 | $88 |
| Triamcinolone Acetonide | 58 | $743 | $13 |
| Doxycycline Hyclate | 11 | $531 | $48 |
| Ketoconazole | 11 | $245 | $22 |
| Hydrocortisone | 17 | $167 | $10 |
| Mupirocin | 15 | $120 | $8 |
2017: 9 drugs
| Humira | 18 | $194,457 | $10,803 |
| Metronidazole | 25 | $2,303 | $92 |
| Clobetasol Propionate | 23 | $2,189 | $95 |
| Doxycycline Hyclate | 20 | $1,546 | $77 |
| Clindamycin Phosphate | 15 | $1,178 | $79 |
| Ketoconazole | 30 | $851 | $28 |
| Doxepin | 15 | $831 | $55 |
| Triamcinolone Acetonide | 21 | $337 | $16 |
| Mupirocin | 25 | $181 | $7 |
2016: 9 drugs
| Humira | 13 | $51,290 | $3,945 |
| Clobetasol Propionate | 19 | $3,806 | $200 |
| Fluorouracil | 12 | $1,910 | $159 |
| Doxepin | 12 | $1,755 | $146 |
| Doxycycline Hyclate | 14 | $1,530 | $109 |
| Metronidazole | 17 | $1,475 | $87 |
| Clindamycin Phosphate | 12 | $1,104 | $92 |
| Ketoconazole | 31 | $955 | $31 |
| Triamcinolone Acetonide | 34 | $610 | $18 |
2015: 8 drugs
| Humira | 13 | $45,055 | $3,466 |
| Clobetasol Propionate | 40 | $12,633 | $316 |
| Doxycycline Hyclate | 27 | $3,390 | $126 |
| Fluorouracil | 13 | $2,116 | $163 |
| Desonide | 16 | $1,794 | $112 |
| Methotrexate | 11 | $1,202 | $109 |
| Ketoconazole | 29 | $859 | $30 |
| Triamcinolone Acetonide | 37 | $618 | $17 |
2014: 12 drugs
| Cordran | 13 | $5,872 | $452 |
| Desonide | 29 | $5,029 | $173 |
| Clobetasol Propionate | 51 | $2,445 | $48 |
| Triamcinolone Acetonide | 54 | $1,090 | $20 |
| Doxycycline Hyclate | 12 | $1,007 | $84 |
| Fluocinonide | 17 | $988 | $58 |
| Clindamycin Phosphate | 16 | $584 | $36 |
| Ketoconazole | 28 | $527 | $19 |
| Lidocaine Hcl Viscous | 19 | $486 | $26 |
| Hydroxyzine | 12 | $204 | $17 |
| Cephalexin | 12 | $132 | $11 |
| Terbinafine | 12 | $119 | $10 |
2013: 4 drugs
| Desonide | 16 | $1,975 | $123 |
| Clobetasol Propionate | 34 | $958 | $28 |
| Triamcinolone Acetonide | 47 | $923 | $20 |
| Hydrocortisone | 11 | $160 | $15 |
Money from drug and device companies
$4,974 in 2025
| 2025 | 2 | 2 | $4,950 | $4,974 |
| 2023 | 2 | 3 | None | $18,212 |
| 2022 | 1 | 1 | None | $18,750 |
| 2021 | 3 | 6 | $20,130 | $20,130 |
| 2020 | 1 | 2 | $2,926 | $2,926 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| SpringWorks Therapeutics | Gomekli | $4,950 | 1 payment
|
| Alexion Pharmaceuticals | None | $24 | 1 payment
|
See all 2 published payments
| SpringWorks Therapeutics | Consulting · 2025-07-18 | Gomekli | $4,950 |
| Alexion Pharmaceuticals | Meals · 2025-06-21 | None | $24 |
See earlier years (2023, 2022, 2021, 2020)
2023: $18,212
| Genentech | None | $18,182 | 1 payment
|
| Pfizer | Cibinqo | $31 | 2 payments
|
2022: $18,750
| Genentech | None | $18,750 | 1 payment
|
2021: $20,130
| UCB GmbH | None | $9,130 | 4 payments
|
| Almirall | None | $7,700 | 1 payment
|
| LEO Pharma AS | None | $3,300 | 1 payment
|
2020: $2,926
| LEO Pharma AS | None | $2,926 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| UCB SA · 2021 | Their institution | $200,408 |
| LEO Pharma AS · As Stnfd Bcc · 2021 | Their institution | $59,332 |
| LEO Pharma AS · 2020 | Their institution | $39,560 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1851565956
- Licence
- CA A109187California A109187: Current · expires 2026-11-30
- Trained
- Stanford University School of Medicine, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 455 Broadway, Discovery Hall,1st Floor,D143, Redwood City, CA, 94063
- NPI first listed
- 2008-04-18
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3240 Alpine Rd, Portola Valley, CA, 94028 · 450 Broadway St, Redwood City, CA, 94063